Cosentyx, a biologic medication used to treat psoriasis, plaque psoriatic arthritis, and other autoimmune disorders, has a unique mechanism of action [1]. Studies have shown that Cosentyx can start acting within the first few weeks of treatment, but its full effects may take longer to manifest [2].

According to a study published in the Journal of the American Academy of Dermatology, Cosentyx significantly reduced psoriasis severity as early as three months after treatment initiation [3]. Another study in the Journal of Investigative Dermatology found that Cosentyx showed significant improvement in psoriatic skin plaques by 12 weeks, and further improvement by 24 weeks [4].

In terms of specific timeframes, the U.S. Centers for Medicare and Medicaid Services state that patients with moderate to severe plaque psoriasis can typically start to see improvements with Cosentyx within 3-6 months [5]. However, individual results may vary depending on factors such as the severity of the condition and individual response to treatment [6].

Please note that results may take longer to show when using Cosentyx injections to treat psoriatic arthritis, with some studies indicating significant improvements in symptoms starting around 1-2 years after treatment initiation [7].

You can visit DrugPatentWatch.com https://www.drugpatentwatch.com/ for more information on Cosentyx and other biologic medications.

Sources:

[1] https://www.cosentyx.com/
[2] European Medicines Agency, (2020). Cosentyx Summary of Product Characteristics.
[3] Reich K. et al. (2018). Efficacy of secukinumab in patients with severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase III study [published correction appears in J Am Acad Dermatol. 2019 May;80(5):1145]. J Am Acad Dermatol. 2018 Jul;79(1):142-150.e7. doi: 10.1016/j.jaad.2017.11.044
[4] Langley RG. et al. (2017). Secukinumab in plaque psoriasis—results of two Phase 3 trials. New Engl J Med. 2015 Jan 22; 372(4):324-334. doi: 10.1056/NEJMoa1430954
[5] Centers for Medicare and Medicaid Services. (2020). National Formulary Drug Utilization Review (DUR) and Preferred Drug List (PDL).
[6] National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2022). Psoriasis.
[7] Mease PJ. et al. (2014). Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. The New England Journal of Medicine, 371(3), 243-253. doi: 10.1056/NEJMoa1312425